Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 31;15(9):1088.
doi: 10.3390/ph15091088.

Binding of Natural Inhibitors to Respiratory Complex I

Jonathan Schiller  1   2 , Volker Zickermann  1   2
Affiliations
Review

Binding of Natural Inhibitors to Respiratory Complex I

Jonathan Schiller et al. Pharmaceuticals (Basel). .

Abstract

NADH:ubiquinone oxidoreductase (respiratory complex I) is a redox-driven proton pump with a central role in mitochondrial oxidative phosphorylation. The ubiquinone reduction site of complex I is located in the matrix arm of this large protein complex and connected to the membrane via a tunnel. A variety of chemically diverse compounds are known to inhibit ubiquinone reduction by complex I. Rotenone, piericidin A, and annonaceous acetogenins are representatives of complex I inhibitors from biological sources. The structure of complex I is determined at high resolution, and inhibitor binding sites are described in detail. In this review, we summarize the state of knowledge of how natural inhibitors bind in the Q reduction site and the Q access pathway and how their inhibitory mechanisms compare with that of a synthetic anti-cancer agent.

Keywords: NADH dehydrogenase; Parkinson’s disease; acetogenin; mitochondria; piericidin; respiratory chain; rotenone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Complex I inhibitors and structural basis of Q binding and reduction. Chemical structures of (A) ubiquinone (Q10, n = 10), (B) piericidin A, (C) an annonaceous acetogenin, (D) rotenone, and (E) IACS-2858 (THF = tetrahydrofuran ring, THP = tetrahydropyran ring). (F) Architecture of respiratory complex I with NDUFS7 (blue), NDUFS2(green), and ND1 (pink), and the Q tunnel. The viewpoint is indicated and the section of the detail view in Figure 2 and Figure 3 is highlighted by a box. (G) Detail view of the Q reduction site and access pathway as shown in Figure 2 and Figure 3; a tyrosine and a histidine residue of NDUFS2 play a key role for binding the Q head group (compare Figure 2, residue numbers see Table 1, for details see text).
Figure 2
Figure 2
Q-binding sites in respiratory complex I. Q reduction site near FeS cluster N2 and access pathway for Q from the membrane with NDUFS7 (blue), NDUFS2 (green), and ND1 (pink) (compare Figure 1); Q molecules and residues discussed in the text are shown in stick representation (numbering see Table 1). (A) Q10 bound to complex I from B. taurus in lipid nanodisc (PDB ID 7QSK), (B) native Q9 in the Q access pathway of complex I from Y. lipolytica (PDB ID 6RFR), (C) head group of decyl benzoquinone (DBQ) bound to complex I from Y. lipolytica captured under turnover (PDB ID 7O6Y), and (D) DBQ bound to complex I from T. thermophilus (PDB ID 6I0D).
Figure 3
Figure 3
Binding of natural inhibitors and IACS-2858 to respiratory complex I. Q reduction site near FeS cluster N2 and access pathway as shown in Figure 2. (A) Piericidin A bound to complex I from M. musculus (PDB ID 6ZTQ), (B) two rotenone molecules bound to complex I from O. aries (PDB ID 6ZKN), (C) annonaceous acetogenin (compound 1 as described in Grba et al., 2022) bound to complex I from M. musculus (PDB ID 7PSA), and (D) the synthetic anti-cancer agent IACS-2858 bound to complex I from M. musculus (PDB ID 7B93); for residue numbering see Table 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hirst J. Mitochondrial complex I. Annu. Rev. Biochem. 2013;82:551–575. doi: 10.1146/annurev-biochem-070511-103700. - DOI - PubMed
    1. Galemou Yoga E., Angerer H., Parey K., Zickermann V. Respiratory complex I—Mechanistic insights and advances in structure determination. Biochim. Biophys. Acta. 2020;1861:148153. doi: 10.1016/j.bbabio.2020.148153. - DOI - PubMed
    1. Kampjut D., Sazanov L.A. Structure of respiratory complex I—An emerging blueprint for the mechanism. Curr. Opin. Struct. Biol. 2022;74:102350. doi: 10.1016/j.sbi.2022.102350. - DOI - PMC - PubMed
    1. Rodenburg R.J. Mitochondrial complex I-linked disease. Biochim. Biophys. Acta. 2016;1857:938–945. doi: 10.1016/j.bbabio.2016.02.012. - DOI - PubMed
    1. Hock D.H., Robinson D.R.L., Stroud D.A. Blackout in the powerhouse: Clinical phenotypes associated with defects in the assembly of OXPHOS complexes and the mitoribosome. Biochem. J. 2020;477:4085–4132. doi: 10.1042/BCJ20190767. - DOI - PMC - PubMed

LinkOut - more resources